BIOACCORD SYSTEM WITH ACQUITY PREMIER - Routine Biopharmaceutical Analysis – Accelerated

Importance of the Topic

Liquid chromatography mass spectrometry is essential for quality control of biopharmaceutical products. Achieving high efficiency and robust data quality across multiple product attributes in a single assay addresses key industrial demands. Integrated systems that reduce complexity and training requirements can broaden access to LC MS in compliance environments.

Study Objectives and Overview

This document introduces the Waters BioAccord System combined with ACQUITY Premier to streamline routine biopharmaceutical analysis. It aims to demonstrate how integrated hardware, software, and guided workflows accelerate deployment and support multi attribute methods from intact mass to glycan profiling. The system is designed to deliver consistent, compliance ready data with minimal specialist intervention.

Methodology

The workflow leverages automated setup, intelligent monitoring through SmartMS, and outcome based application training. Guided protocols cover intact mass analysis, peptide mapping and multi attribute method development, released glycan profiling, and impurity measurement in proteins, peptides, and oligonucleotides. Data acquisition and processing occur within a single informatics platform offering audit trails and role based access.

Used Instrumentation

• BioAccord LC MS System equipped with ACQUITY Premier UPLC
• MaxPeak High Performance Surfaces to minimize metal surface adsorption
• SmartMS software for automated health checks and diagnostics
• waters_connect informatics platform for compliant data management

Main Results and Discussion

In comparative tests the ACQUITY Premier flow paths reduced peak broadening and improved recovery of metal sensitive peptides and oligonucleotides. Extracted ion chromatograms for a model peptide showed higher signal intensity and lower variability than conventional systems. Oligonucleotide impurity analysis revealed previously undetected low level species. Fragment ion spectra confirmed enhanced sensitivity and reproducibility across multiple product attributes.

Benefits and Practical Applications

The integrated system reduces setup time and training overhead, enabling existing staff to perform complex assays. Simultaneous detection, identification, and quantification accelerate decision making and lower operational risk. Compliance ready software supports audit trails, electronic records, and network deployment for regulated environments. Laboratories can adopt LC MS for QA QC release testing without major infrastructure changes.

Future Trends and Opportunities

As biopharmaceutical pipelines expand, demand for automated multi attribute analysis will grow. Advances in surface chemistries and informatics integration will further enhance throughput and data reliability. Future developments may include high throughput screening, real time monitoring in manufacturing, and expanded support for novel modalities such as lipid nanoparticles and mRNA fragments.

Conclusion

The BioAccord System with ACQUITY Premier delivers a robust, user friendly platform for routine biopharmaceutical LC MS analysis. By combining optimized hardware surfaces, guided workflows, and compliance ready informatics, it democratizes multi attribute testing and supports regulatory requirements while maintaining high data quality.